ARDX
ARDELYX, INC.Company Information
- Company Name
- ARDELYX, INC.
- CIK
- CIK0001437402
- Category
- Large accelerated filer
- Ticker: Exchange
- ARDX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ARDX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-02-20
- Last sale
- 2026-08-21
- Shares purchased (TTM)
- 333,333
- Shares sold (TTM)
- 928,523
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 177,861,503
- Shares outstanding
- 248,067,253
- Ownership
- 71.70%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -21.77%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 97 | 31 | 68 | 43 | 90 | 31 | 65 | 47 | 42 | 36 | 21 | 34 | ||||||
| Available For Sale Securities Debt Securities Current | 185 | 207 | 197 | 200 | 148 | 183 | 185 | 143 | 144 | 166 | 163 | 131 | ||||||
| Accounts Receivable Net Current | 100 | 83 | 72 | 77 | 63 | 46 | 58 | 53 | 37 | 28 | 22 | 43 | ||||||
| Inventory Gross | 26 | 23 | 18 | 25 | 22 | 24 | 21 | 11 | 14 | 10 | 12 | 9 | ||||||
| Prepaid Expense And Other Assets Current | 19 | 24 | 14 | 15 | 16 | 15 | 11 | 12 | 11 | 12 | 8 | 7 | ||||||
| Assets Current | 442 | 382 | 382 | 368 | 352 | 313 | 356 | 284 | 263 | 258 | 246 | 241 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Inventory Noncurrent | 113 | 105 | 105 | 104 | 101 | 82 | 70 | 74 | 70 | 69 | 37 | 39 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 5 | 5 | 5 | 4 | 2 | 4 | 4 | 5 | 6 | 7 | ||||||
| Other Assets Noncurrent | 7 | 7 | 7 | 7 | 7 | 7 | 5 | 5 | 5 | 6 | 4 | 2 | ||||||
| Assets | 576 | 505 | 502 | 486 | 467 | 410 | 436 | 368 | 343 | 342 | 298 | 289 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 38 | 28 | 19 | 18 | 22 | 14 | 16 | 16 | 11 | 17 | 11 | 8 | ||||||
| Employee Related Liabilities Current | 15 | 9 | 19 | 15 | 12 | 7 | 15 | 12 | 10 | 7 | 13 | 8 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 4 | 4 | 4 | 4 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Contract With Customer Liability Current | 7 | 3 | 1 | 7 | 6 | 11 | 11 | 7 | 11 | 7 | 7 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 71 | 67 | 48 | 42 | 41 | 43 | 35 | 33 | 27 | 22 | 15 | 19 | ||||||
| Liabilities Current | 132 | 110 | 89 | 83 | 82 | 76 | 78 | 70 | 62 | 57 | 50 | 44 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 4 | 4 | 4 | 3 | 1 | 1 | 1 | 1 | 2 | 3 | ||||||
| Long Term Loans Payable | 252 | 204 | 203 | 202 | 201 | 151 | 151 | 101 | 100 | 100 | 50 | 27 | ||||||
| Contract With Customer Liability Noncurrent | 14 | 14 | 14 | 14 | 12 | 8 | 7 | 13 | 10 | 12 | 9 | 10 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Liabilities | 427 | 356 | 335 | 332 | 327 | 265 | 262 | 210 | 196 | 191 | 131 | 98 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,150 | 1,133 | 1,114 | 1,101 | 1,085 | 1,072 | 1,059 | 1,048 | 1,036 | 1,024 | 1,013 | 1,009 | ||||||
| Retained Earnings Accumulated Deficit | -1,001 | -985 | -947 | -947 | -946 | -926 | -885 | -890 | -889 | -873 | -846 | -817 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Stockholders Equity | 149 | 149 | 167 | 154 | 140 | 146 | 173 | 158 | 147 | 151 | 167 | 191 | ||||||
| Liabilities And Stockholders Equity | 576 | 505 | 502 | 486 | 467 | 410 | 436 | 368 | 343 | 342 | 298 | 289 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 249 | 247 | 244 | 243 | 241 | 239 | 238 | 237 | 235 | 234 | 232 | 232 | ||||||
| Shares Outstanding | 249 | 247 | 244 | 243 | 241 | 239 | 238 | 237 | 235 | 234 | 232 | 232 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialARDELYX, INC. (ARDX) — SEC Financial Statements & Analysis
ARDELYX, INC. (ARDX) is a pharmaceutical preparations company, incorporated in DE. ARDELYX, INC. trades on Nasdaq as: ARDX. ARDELYX, INC. (ARDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, ARDELYX, INC. carries a market cap of $1.27B, a P/E ratio of -22.71x, a P/B ratio of 8.49x, a P/S ratio of 2.81x, an enterprise value of $1.17B, and an EV/EBITDA multiple of -36.38x. On profitability, it posts a gross margin of 94.37%, an operating margin of -7.86%, a net margin of -12.35%, a Return on Equity (ROE) of -38.61%, a Return on Assets (ROA) of -10.68%, and a Return on Invested Capital (ROIC) of -60.06%. Per share, it reports EPS of $-0.22, diluted EPS of $-0.22, free cash flow per share of $-0.07, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 16.77% year-over-year, net income growth of -1.21% year-over-year, and EPS growth of -4.46% year-over-year. On the balance sheet, it maintains a current ratio of 3.34x, a quick ratio of 3.00x, working capital of $309.71M, a debt-to-equity ratio of 2.86x, a debt ratio of 0.74, an interest coverage ratio of -1.60x, free cash flow of $-17.92M (TTM), and net debt of $-97.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.27B
- P/E TTM
- -22.71x
- EPS TTM
- $-0.22
- P/B TTM
- 8.49x
- ROE TTM
- -38.61%
- ROA TTM
- -10.68%
- Debt To Equity
- 2.86x
- Free Cash Flow TTM
- $-17.92M
- Net Revenue TTM Growth 1Y
- 16.77%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ARDELYX, INC. in?
ARDELYX, INC. (ARDX) operates in the Pharmaceutical Preparations industry.
What exchange does ARDX trade on?
ARDELYX, INC. (ARDX) trades on the Nasdaq.
Where is ARDELYX, INC. incorporated?
ARDELYX, INC. is incorporated in DE.
When was ARDELYX, INC. (ARDX)'s most recent SEC filing?
ARDELYX, INC. (ARDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ARDX's market cap?
ARDELYX, INC. (ARDX) has a market capitalization of $1.27B as of 2026-06-30.
What is ARDX's EPS (earnings per share)?
ARDELYX, INC. (ARDX)'s trailing twelve month EPS is $-0.22 as of 2026-06-30.
What is ARDX's ROE (return on equity)?
ARDELYX, INC. (ARDX)'s trailing twelve month Return on Equity (ROE) is -38.61% as of 2026-06-30.
What is ARDX's ROA (return on assets)?
ARDELYX, INC. (ARDX)'s trailing twelve month Return on Assets (ROA) is -10.68% as of 2026-06-30.
What is ARDX's ROIC (return on invested capital)?
ARDELYX, INC. (ARDX)'s trailing twelve month Return on Invested Capital (ROIC) is -60.06% as of 2026-06-30.
What is ARDX's EV/EBITDA?
ARDELYX, INC. (ARDX)'s trailing twelve month EV/EBITDA is -36.38x as of 2026-06-30.